These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 35690723)

  • 21. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives.
    De Matteis E; Guglielmetti M; Ornello R; Spuntarelli V; Martelletti P; Sacco S
    Expert Rev Neurother; 2020 Jun; 20(6):627-641. PubMed ID: 32434430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.
    Khan S; Olesen A; Ashina M
    Cephalalgia; 2019 Mar; 39(3):374-389. PubMed ID: 29110503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R; Olesen J
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medications Approved for Preventing Migraine Headaches.
    Spindler BL; Ryan M
    Am J Med; 2020 Jun; 133(6):664-667. PubMed ID: 32145209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
    Xu D; Chen D; Zhu LN; Tan G; Wang HJ; Zhang Y; Liu L
    Cephalalgia; 2019 Aug; 39(9):1164-1179. PubMed ID: 30789292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational Cohort Studies.
    Ferreira VL; Mainka FF; Wiens A; Pontarolo R
    Clin Drug Investig; 2023 Sep; 43(9):669-680. PubMed ID: 37665501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
    Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis.
    Fernández-Bravo-Rodrigo J; Pascual-Morena C; Flor-García A; Saz-Lara A; Sequí-Dominguez I; Álvarez-Bueno C; Barreda-Hernández D; Cavero-Redondo I
    Int J Environ Res Public Health; 2022 Feb; 19(3):. PubMed ID: 35162776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine.
    Reuter U
    Headache; 2018 May; 58 Suppl 1():48-59. PubMed ID: 29697156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigens and Antibodies in Disease With Specifics About CGRP Immunology.
    Taylor FR
    Headache; 2018 Nov; 58 Suppl 3():230-237. PubMed ID: 30187471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review.
    Tfelt-Hansen P; Diener HC; Steiner TJ
    Cephalalgia; 2020 Jan; 40(1):122-126. PubMed ID: 31547694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
    Maasumi K; Michael RL; Rapoport AM
    Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
    CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The sense of stopping migraine prophylaxis.
    Al-Hassany L; Lyons HS; Boucherie DM; Farham F; Lange KS; Marschollek K; Onan D; Pensato U; Storch E; Torrente A; Waliszewska-Prosół M; Reuter U;
    J Headache Pain; 2023 Feb; 24(1):9. PubMed ID: 36792981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapies targeting CGRP signaling for medication overuse headache.
    Koumprentziotis IA; Mitsikostas DD
    Curr Opin Neurol; 2022 Jun; 35(3):353-359. PubMed ID: 35674079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CGRP pathway monoclonal antibodies for cluster headache.
    Chan C; Goadsby PJ
    Expert Opin Biol Ther; 2020 Aug; 20(8):947-953. PubMed ID: 32241175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anti-calcitonin generelated peptide (CGRP) therapies for migraine].
    Moisset X; Demarquay G
    Rev Prat; 2023 Feb; 73(2):123-126. PubMed ID: 36916250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.
    Schuster NM; Rapoport AM
    Clin Neuropharmacol; 2017; 40(4):169-174. PubMed ID: 28644160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
    Tringali G; Navarra P
    Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.